Partnerships

What Ardana Offers

R & D

Ardana provides discovery and development support in complementary fields which share common biological mechanisms with the reproductive tract. These include: 

  • Oncology
  • Inflammation
  • Immunology

Ardana has unique intellectual property, know-how, access to in-vitro and in-vivo models and a growing portfolio of novel, multi-indication targets. Collaborative partners gain access to this expertise and can thereby fast track the discovery and development of novel reproductive therapies at low risk. Ardana also provides unique formulation and delivery technologies, which can be applied to partner products.

 

Licensing/Partnering Opportunities

Ardana has clearly defined therapeutic areas of interest:

 

  • Androgen replacement therapy
  • Reproductive endocrinology
  • Urology – e.g. prostate cancer, Benign Prostatic Hyperplasia (BPH)
  • Gynaecology – e.g. menstrual disorders, endometriosis, infertility
  • Sexual dysfunction
  • Obstetrics – e.g. cervical ripening, pre-eclampsia
  • Contraception

If you are seeking a partner in the area of human reproductive health, then please contact Ardana at info@ardana.co.uk

 

Co Development Opportunities

Ardana is also interested in co-developing strategic products with partners who bring supplementary resources and expertise to accelerate their development.

Ardana is currently seeking either licensing or co-development partners for the products listed below. If you would like further information, please email us: info@ardana.co.uk

Products

Potential Indications

Stage of Development

Details

Teverelix LA sustained release formulation

prostate cancer (PC);benign prostatic hyperplasia (BPH);endometriosis; uterine fibroids

Phase II clinical proof of concept completed for PC and BPH ; Phase I endometriosis

GnRH antagonist

 

Teverelix IR
immediate release formulation

 

controlled ovarian stimulation (COS);assisted reproductive technology (ART).

 

Phase I completed

 

GnRH antagonist

 

Leuprorelin implants

 

Prostate cancer

 

Phase II

 

3-4 month duration of delivery GnRH agonist

 

EP80317 (cardiovascular,
CD36)

 

atherosclerosis; hypercholesterolemia

 

Pre-clinical

 

In models EP80317 has been shown to reduce the formation of atherosclerotic plaques in the aorta, reverse existing plaques, as well as decreasing plasma cholesterol

 

Research programmes

 

Wound healing and immune tolerance

 

Research – proof of concept in models

 

Synergistic combinations of cytokines, prostaglandins and PDE IV

 

Prostanoid Receptor Antagonists

 

Pathological conditions of the uterus including dysmenorrhoea and menorrhagia

 

Research

 

EP4 and/or EP2, FP, PGF2, IP

 

Additional candidates are being considered for reformulation to either improve the safety and/or efficacy profile and/or patient acceptability of currently marketed, but off patent compounds, using Ardana’s oral and transdermal technology platforms.